Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ascendis Pharma A/S (ASND) vs Walmart Stores Inc (WMT) Price & Performance

Ascendis Pharma A/STrade
Walmart Stores IncTrade

Price performance (Past 24H)

Key statistics

Ascendis Pharma A/S vs Walmart Stores Inc — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.78B), while Walmart Stores Inc trades at $113.02 (market cap $896.56B). The key difference: Walmart Stores Inc is far larger — about 53.4× Ascendis Pharma A/S's market cap, and Walmart Stores Inc pays a 0.88% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.

ASNDWMT
Market Cap
$16.78B$896.56B
Sector
HealthConsumer Staples
52-Week High
$277.18$134.20
52-Week Low
$189.74$96.05
Enterprise Value
$17.15B$960.01B
Volume
5,675,288
Dividend Yield
0.88%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ascendis Pharma A/S

Ascendis Pharma (ASND) trades at $255.41, up 2.23% with a bullish technical signal. The company shows strong revenue growth from $364M in 2024 to $720M in 2025, though remains unprofitable with a net loss of $228M. Recent news highlights positive clinical trial results for achondroplasia treatments and inclusion in Russell indexes. Analyst consensus is strongly bullish with 92% buy ratings and a $309.75 price target, representing 21% upside potential.

ASND presents significant growth potential with multiple product launches and expanding rare endocrine franchise, but carries substantial risk due to negative equity, high debt levels, and ongoing losses. The transition to profitability projected for 2026 with $496M net income represents a key inflection point. Investors should weigh the strong analyst optimism against the company's financial leverage and execution risks in drug commercialization.

Walmart Stores Inc

Walmart (WMT) stock trades at $113.26, up 1.26% today, with a neutral technical signal and strong analyst consensus. The company demonstrates robust fundamentals with revenue growth to $681.0B in 2025 and net income of $19.4B, alongside consistent earnings beats. Recent news highlights operational innovations like drone delivery expansion and AI tools, while maintaining a solid dividend.

Outlook remains positive with a $142 consensus price target, though risks include competitive pressures and margin sustainability. The stock presents a long-term opportunity given its defensive positioning and growth initiatives, but investors should monitor execution against Amazon and consumer spending trends.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

Read more on ASND

About Walmart Stores Inc

Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.

Read more on WMT